Effectiveness and Safety of Cannabinoids as an Add-On Therapy in the Treatment of Resistant Spasticity in Multiple Sclerosis: A Systematic Review
Cannabis & Cannabinoid Research · 01.08.2023 · 8 (4) · 580-588
DOI: 10.1089/can.2022.0254 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cannabis & Cannabinoid Research, online erschienen am 09.08.2023. Verfasst von Carmen Martinez-Paz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Medicine and Public Health, Faculty of Medicine, University of Seville, Seville, Spain. Hauptthemen laut MEDLINE: Cannabinoids, Multiple Sclerosis, Cannabidiol, Cannabis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
Spasticity continues to be a very prevalent, highly invalidating, and difficult-to-manage symptom in patients with multiple sclerosis (MS). The aim of this systematic review is to evaluate the effectiveness of the use of cannabis and cannabinoids in these patients, evaluating its use as an additional therapy.
Methods
We performed a systematic review of the literature searching in the major scientific databases (PubMed, Scopus, EMBASE, WOS, and Cochrane Library) for articles from January 2017 to May 2022 containing information about the effectiveness of cannabis and cannabinoids in patients with insufficient response to first-line oral antispastic treatment.
Results
A total of five medium high-quality articles were selected to be part of the study and all evaluated the effectiveness of the tetrahydrocannabinol (THC) and cannabidiol (CBD) spray. The effectiveness of this drug and the significant improvements are produced on the patient-related spasticity assessment scales, obtaining improvement up to 45%; and on quality of life, producing a decrease in the appearance of symptoms related to spasticity, as well as an increase in the development of basic activities of daily living. The average dose is 5–7 sprays/day. The discontinuation rate for these treatments is around 40% due to lack of effectiveness and adverse events. All reported adverse effects are mild to moderate in severity and their incidence is ∼17%, although this figure tends to decrease with drug use.
Conclusions
Adding the THC:CBD sprays have been shown to be more effective in treating MS spasticity than optimizing the dose of first-line antispastic drugs in selected responders patients. The safety and tolerability profiles remain in line with those obtained in other trials. More patients would benefit from treatment if the initial response search period was extended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Preventive Medicine and Public Health, Faculty of Medicine, University of Seville, Seville, Spain.
ORCID-Profile: Emilio García-Cabrera
Zitieren
APA
Martinez-Paz, C., García-Cabrera, E., & Vilches-Arenas, Á. (2023). Effectiveness and Safety of Cannabinoids as an Add-On Therapy in the Treatment of Resistant Spasticity in Multiple Sclerosis: A Systematic Review. Cannabis & Cannabinoid Research, 8(4), 580-588. https://doi.org/10.1089/can.2022.0254
Vancouver
Martinez-Paz C, García-Cabrera E, Vilches-Arenas Á. Effectiveness and Safety of Cannabinoids as an Add-On Therapy in the Treatment of Resistant Spasticity in Multiple Sclerosis: A Systematic Review. Cannabis & Cannabinoid Research. 2023;8(4):580-588. doi:10.1089/can.2022.0254
BibTeX
@article{MartinezPaz2023,
author = {Martinez-Paz, Carmen and García-Cabrera, Emilio and Vilches-Arenas, Ángel},
title = {Effectiveness and Safety of Cannabinoids as an Add-On Therapy in the Treatment of Resistant Spasticity in Multiple Sclerosis: A Systematic Review},
journal = {Cannabis & Cannabinoid Research},
year = {2023},
volume = {8},
number = {4},
pages = {580--588},
doi = {10.1089/can.2022.0254}
}
EUVIMED